Diagnosis and treatment of ascites

Published:January 21, 2017DOI:
      Ascites is the most common complication of cirrhosis and its development is a sign of significant portal hypertension.
      • Tsochatzis E.A.
      • Bosch J.
      • Burroughs A.K.
      Liver cirrhosis.
      At a volume of more than 1.5 l ascites usually can be detected by physical examination. Ascites in cirrhosis is the result of a vicious cycle involving arterial splanchnic vasodilation, decreased effective blood volume (despite a compensatory increase in cardiac output), renal vasoconstriction with resulting sodium retention, and finally extracellular fluid retention.
      • Arroyo V.
      • Colmenero J.
      Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management.
      Systemic inflammation can exacerbate portal hypertension, contribute to the development of ascites, and impair prognosis.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Hepatology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Tsochatzis E.A.
        • Bosch J.
        • Burroughs A.K.
        Liver cirrhosis.
        Lancet. 2014; 383: 1749-1761
        • Arroyo V.
        • Colmenero J.
        Ascites and hepatorenal syndrome in cirrhosis: pathophysiological basis of therapy and current management.
        J Hepatol. 2003; 38: S69-S89
        • Wiest R.
        • Krag A.
        • Gerbes A.
        Spontaneous bacterial peritonitis: recent guidelines and beyond.
        Gut. 2012; 61: 297-310
        • Jalan R.
        • Fernandez J.
        • Wiest R.
        • Schnabl B.
        • Moreau R.
        • Angeli P.
        • et al.
        Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013.
        J Hepatol. 2014; 60: 1310-1324
        • Piano S.
        • Fasolato S.
        • Salinas F.
        • Romano A.
        • Tonon M.
        • Morando F.
        • et al.
        The empirical antibiotic treatment of nosocomial spontaneous bacterial peritonitis: Results of a randomized, controlled clinical trial.
        Hepatology. 2016; 63: 1299-1309
      1. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis.
        J Hepatol. 2010; 53: 397-417
        • Arroyo V.
        • Gines P.
        • Gerbes A.L.
        • Dudley F.J.
        • Gentilini P.
        • Laffi G.
        • et al.
        Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club.
        Hepatology. 1996; 23: 164-176
        • Bernardi M.
        • Caraceni P.
        • Navickis R.J.
        • Wilkes M.M.
        Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials.
        Hepatology. 2012; 55: 1172-1181
        • Mookerjee R.P.
        • Pavesi M.
        • Thomsen K.L.
        • Mehta G.
        • Macnaughtan J.
        • Bendtsen F.
        • et al.
        Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure.
        J Hepatol. 2016; 64: 574-582
        • Leithead J.A.
        • Rajoriya N.
        • Tehami N.
        • Hodson J.
        • Gunson B.K.
        • Tripathi D.
        • et al.
        Non-selective beta-blockers are associated with improved survival in patients with ascites listed for liver transplantation.
        Gut. 2015; 64: 1111-1119
        • Salerno F.
        • Camma C.
        • Enea M.
        • Rossle M.
        • Wong F.
        Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data.
        Gastroenterology. 2007; 133: 825-834
        • Rossle M.
        • Gerbes A.L.
        TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax: a critical update.
        Gut. 2010; 59: 988-1000